| **SPONSOR, TYPE OF SUBMISSION** | **DRUG TYPE AND USE** | **LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION** | **PBAC OUTCOME** |
| --- | --- | --- | --- |
| OZANIMOD  Capsule 230 micrograms  Capsule 460 micrograms  Capsule 920 micrograms  Zeposia®  Celgene Pty Ltd  New listing  (Matters outstanding) | Relapsing-remitting multiple  sclerosis (RRMS) | To request an Authority Required listing for the treatment of patients with RRMS. | The PBAC recommended, out of session, the Authority Required (STREAMLINED) listing of ozanimod for the treatment of relapsing remitting multiple sclerosis (RRMS) on a cost-minimisation basis with fingolimod, following confirmation ozanimod was now TGA registered. The PBAC noted ozanimod was not TGA registered when previously considered at its March 2020 meeting.  In making this recommendation, the PBAC recalled its March 2020 consideration and reaffirmed its view that based on the available evidence, ozanimod was of superior comparative efficacy to interferon beta-1a and likely to be of non-inferior comparative safety and efficacy to fingolimod. |